EFFECTS OF CHROMIUM SUPPLEMENTATION ON SERUM HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS IN MEN TAKING BETA-BLOCKERS - A RANDOMIZED, CONTROLLED TRIAL

被引:63
作者
ROEBACK, JR
HLA, KM
CHAMBLESS, LE
FLETCHER, RH
机构
[1] VET AFFAIRS MED CTR, DURHAM, NC USA
[2] UNIV N CAROLINA, DEPT BIOSTAT, COLLABORAT STUDIES COORDINATING CTR, CHAPEL HILL, NC 27514 USA
[3] DUKE UNIV, MED CTR, DURHAM, NC 27710 USA
关键词
D O I
10.7326/0003-4819-115-12-917
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To determine the efficacy of glucose tolerance factor (GTF)-chromium for increasing serum levels of high-density lipoprotein (HDL) cholesterol in patients taking beta-blockers. Design: Randomized, double-blind, placebo-controlled trial. Setting: Mixed primary and referral-based outpatient clinic at a university-affiliated VA Medical Center. Patients: Referred sample of 72 men receiving beta-blockers, mainly for hypertension. Sixty-three patients (88%) completed the study. Interventions: Current medications, including beta-blockers, were continued. During the 8-week treatment phase, patients in the chromium group received a total daily dose of 600-mu-g of biologically active chromium divided into three equal doses; control patients received a placebo of identical appearance and taste. Measurements: Serum levels of total cholesterol and HDL cholesterol were measured. Main Results: Mean baseline levels of HDL and total cholesterol (+/- SD) were 0.93 +/- 0.28 mmol/L and 6.0 +/- 1.0 mmol/L (36 +/- 11.1 mg/dL and 232 +/- 38.5 mg/dL), respectively. The difference between groups in adjusted mean change in HDL cholesterol levels, accounting for baseline HDL cholesterol levels, age, weight change, and baseline total cholesterol levels, was 0. 15 mmol/L (5.8 mg/dL) (P = 0.01) with a 95% Cl showing that the treatment effect was > + 0.04 mmol/L (+ 1.4 mg/dL). Mean total cholesterol, triglycerides and body weight did not change significantly during treatment for either group. Compliance as measured by pill count was 85%, and few side effects were reported. Two months after the end of treatment, the between-group difference in adjusted mean change from baseline to end of post-treatment follow-up was - 0.003 mmol/L (-0.1 mg/dL). Conclusion: Two months of chromium supplementation resulted in a clinically useful increase in HDL cholesterol levels in men taking beta-blockers.
引用
收藏
页码:917 / 924
页数:8
相关论文
共 42 条
  • [1] HIGH-DENSITY LIPOPROTEIN CHOLESTEROL, TOTAL CHOLESTEROL SCREENING, AND MYOCARDIAL-INFARCTION - THE FRAMINGHAM-STUDY
    ABBOTT, RD
    WILSON, PWF
    KANNEL, WB
    CASTELLI, WP
    [J]. ARTERIOSCLEROSIS, 1988, 8 (03): : 207 - 211
  • [2] CHROMIUM INTAKE, ABSORPTION AND EXCRETION OF SUBJECTS CONSUMING SELF-SELECTED DIETS
    ANDERSON, RA
    KOZLOVSKY, AS
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1985, 41 (06) : 1177 - 1183
  • [3] EFFECTS OF SUPPLEMENTAL CHROMIUM ON PATIENTS WITH SYMPTOMS OF REACTIVE HYPOGLYCEMIA
    ANDERSON, RA
    POLANSKY, MM
    BRYDEN, NA
    BHATHENA, SJ
    CANARY, JJ
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1987, 36 (04): : 351 - 355
  • [4] EFFECTS OF CHROMIUM SUPPLEMENTATION ON URINARY CR EXCRETION OF HUMAN-SUBJECTS AND CORRELATION OF CR EXCRETION WITH SELECTED CLINICAL-PARAMETERS
    ANDERSON, RA
    POLANSKY, MM
    BRYDEN, NA
    PATTERSON, KY
    VEILLON, C
    GLINSMANN, WH
    [J]. JOURNAL OF NUTRITION, 1983, 113 (02) : 276 - 281
  • [5] CHROMIUM SUPPLEMENTATION OF HUMAN-SUBJECTS - EFFECTS ON GLUCOSE, INSULIN, AND LIPID VARIABLES
    ANDERSON, RA
    POLANSKY, MM
    BRYDEN, NA
    ROGINSKI, EE
    MERTZ, W
    GLINSMANN, W
    [J]. METABOLISM-CLINICAL AND EXPERIMENTAL, 1983, 32 (09): : 894 - 899
  • [6] Borel J. S., 1984, BIOCH ESSENTIAL ULTR, P175
  • [7] CHROMIUM INTAKE AND URINARY CHROMIUM EXCRETION OF TRAUMA PATIENTS
    BOREL, JS
    MAJERUS, TC
    POLANSKY, MM
    MOSER, PB
    ANDERSON, RA
    [J]. BIOLOGICAL TRACE ELEMENT RESEARCH, 1984, 6 (04) : 317 - 326
  • [8] THE UPTAKE AND EXCRETION OF CHROMIUM BY THE ELDERLY
    BUNKER, VW
    LAWSON, MS
    DELVES, HT
    CLAYTON, BE
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 1984, 39 (05) : 797 - 802
  • [9] DEFLORA S, 1989, ARCH TOXICOL S, V313, P28
  • [10] ELWOOD JC, 1982, J AM COLL NUTR, V1, P263